Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H

Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H has 331.74M shares outstanding.

As of December 31, 2025, Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H maintains a current ratio of 0.98, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -5.18, indicating conservative leverage, while an interest coverage ratio of -1.71 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2025. Return on assets (ROA) is negative at -63.07, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 121.00, a quick read on workforce productivity versus industry peers.

These figures are as of the close on October 22, 2026.

Over the twelve months ended December 31, 2025, Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H generated - - in revenue and converted that into -203.11M in net income, yielding earnings per share of -0.62. EBITDA reached -127.46M, while operating income came in at -170.59M.

As of December 31, 2025, Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H holds 262.71M in cash and equivalents against 55.31M in total debt, resulting in a net debt position of -36.12M. Total book value stands at -1.08B, with working capital of -4.68M providing operational flexibility.

Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H produced -152.61M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -18.87M in capital expenditures, free cash flow totaled -171.48M - equivalent to -0.52 per share.